Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Michael Roost Clausen et al.|The Lancet|2021Cited by 337
Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational studyRosa Ruchlemer, Tamar Lachish, Benjamin J. Arthurs et al.|Mycoses|2019Cited by 80
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation DataMartin Hutchings, Pieternella J. Lugtenburg, Michael Roost Clausen et al.|Blood|2020Cited by 64
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E.D. Chamuleau, Marie José Kersten, Rinske Boersma et al.|Haematologica|2019Cited by 53
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working groupDoreen G. Te Raa, Mark‐David Levin, Lina van der Straten et al.|Leukemia & lymphoma/Leukemia and lymphoma|2022Cited by 4